Urinary transforming growth factor ?1 levels in hepatitis C virus-related chronic liver disease: Correlation between high levels and severity of disease

Tsai, Jer‐Chia; Jeng, Jen‐Eing; Chuang, Li‐Yeh; Chang, Wen‐Yu

doi:10.1002/hep.510250516

Cited by 22 publications

(26 citation statements)

References 45 publications

(21 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The plasma TGFb1 levels after treatment resulting in clinical improvement, although decreased, however did not correlate with a-fetoprotein [129]. It has even been suggested that in patients with HCC and low production of a-fetoprotein, a finding of increased TGFb1 concentration in urine may be useful in the diagnosis [131]. In addition, the way of Smad3 phosphorylation, resulting in the creation of two possible isoforms, alters the final effect of TGFb1.…”

Section: Prace Poglądowementioning

confidence: 96%

Transforming growth factor beta1 (TGFbeta1) in physiology and pathology

Kajdaniuk¹,

Marek²,

Borgiel−Marek³

et al. 2013

Endokrynologia Polska

163

118

View full text Add to dashboard Cite

This review describes precisely the consequence of TGFb1 prevalence in the organism, and its significant influence on physiological and pathophysiological processes. Organ and tissue distinctiveness hinder unambiguous characterisation of the cytokine. However, there are constant functions of TGFb1 inducing no controversy: it participates in foetal development, control of cell growth and differentiation, induces fibrosis and scar formation (the process of 'wound healing'), causes the suppression of immune response, is involved in angiogenesis, the development of tumours, and inflammatory processes. Thus, TGFb1 is a multifunctional cytokine. There are three fundamental directions of its activities: I. TGFb1 regulates cell proliferation, growth, differentiation and cells movement. II. TGFb1 has immunomodulatory effects. III. TGFb1 has profibrogenic effects. TGFb1 action can be local and systemic. This review describes TGFb1 in pathology: colitis ulcerosa, Crohn's disease, coeliac disease, diabetic nephropathy, diabetic retinopathy and diabetic foot, pulmonary hypertension, and Alzheimer's disease. TGFb1 and its receptors are also of interest to endocrinologists. Lack of TGFb1-dependent growth control may result in oncogenesis: papillary, follicular and anaplastic thyroid cancers, prostate, breast and uterine cervical cancer, oesophagus, gastric, colorectal and liver cancers, NSCLC, and malignant melanoma. Excessive TGFb1 activity is an integral part of the fibrotic processes occurring in the response to injury. An increased TGFb1 expression has been observed in patients with pulmonary, kidney, and liver fibrosis. In chronic hepatitis, the prolonged stimulation of hepatic stellate cells being the result of chronic damage to hepatocytes results in the release of profibrogenic abundant factors such as TGFb1 and leads to the development of liver cirrhosis. The results of experimental procedures and treatment known as anti-TGFb1 strategy acting against the fibrosis in various tissues leads to hope regarding the use of anti-TGFb1 strategy in clinical practice. StreszczenieW artykule poglądowym szczegółowo opisano konsekwencje rozpowszechnienia TGFb1 w organizmie oraz jego wpływ na szereg procesów fizjologicznych i patofizjologicznych. Istotne odrębności narządowe i tkankowe utrudniają jednoznaczną charakterystykę tej cytokiny. Istnieją jednak stałe funkcje TGFb1 nie wzbudzające kontrowersji: uczestniczy w rozwoju płodu, regulacji wzrostu i różnicowa-nia komórek, indukuje proces włóknienia i bliznowacenia (proces "gojenia rany"), powoduje hamowanie odpowiedzi immunologicznej, uczestniczy w angiogenezie, w rozwoju nowotworów, w procesach zapalnych -jest więc cytokiną wieloczynnościową. Można wyróżnić trzy fundamentalne kierunki jego działania: I -TGFb1 reguluje proliferację, wzrost, różnicowanie i przemieszczanie komórek; II -TGFb1 wykazuje działanie immunomodulujące; III -TGFb1 wykazuje działanie profibrogenne. Działanie TGFb1 może mieć charakter miejscowy i systemowy. Opisano udział TGFb1 w stanach patologicznyc...

show abstract

Section: Prace Poglądowementioning

confidence: 96%

Transforming growth factor beta1 (TGFbeta1) in physiology and pathology

Kajdaniuk¹,

Marek²,

Borgiel−Marek³

et al. 2013

Endokrynologia Polska

163

118

View full text Add to dashboard Cite

show abstract

“…15 A number of serological and urinary compounds such as procollagens, tissue inhibitors of metalloproteinases (TIMP), type IV S collagen, hyaluronic acid, and laminin and mediators of extracellular matrix production such as TGF-␤ have been evaluated as noninvasive markers of liver fibrosis. [16][17][18][19][20][21][22][23][24][25][26] Most of these studies have focused on using these markers in cross-sectional studies to diagnose the stage of liver fibrosis.…”

Section: H Epatitis C Virus (Hcv) Infection Is Character-mentioning

confidence: 99%

Progression of fibrosis in hepatitis C with and without schistosomiasis: Correlation with serum markers of fibrosis

et al. 2006

View full text Add to dashboard Cite

“…Nineteen studies evaluated use of serum AFP for detection of HCC. As shown in Table 1, 10 studies evaluated other serologic markers for HCC, 25,27-31,35,37-39 1 study evaluated urinary transforming growth factor ␤-1, 40 6 studies evaluated hepatic ultrasound (US), 26,[32][33][34][35]40 1 study evaluated computerized tomography (CT) and magnetic resonance imaging (MRI), 30 and 2 studies evaluated CT and US. 26,34 AFP.…”

Section: Resultsmentioning

confidence: 99%

“…Five of these 24 studies were in patients infected with hepatitis C alone, [25][26][27][28][29] and 19 were in patients with hepatitis B or C or both. 18,20,24,[30][31][32][33][34][35][36][37][38][39][40][41][42][43][44][45] Ten of these studies were surveillance studies, 20,24,26,[30][31][32][33][34][35][36] and 14 were screening studies. 18,25,[27][28][29][37][38][39][40][41][42][43][44][45] No study was excluded solely for lack of appropriate histological or pathologic evidence of HCC.…”

Section: Resultsmentioning

confidence: 99%

“…Of 19 studies that evaluated serum AFP for detection of HCC, 3 were in patients with HCV alone, 28,36,46 and 16 were in patients with HCV or hepatitis B virus (HBV) or both. 10,20,27,[30][31][32][33]35,37,39,40,[40][41][42][43][44] Nine of the 10 surveillance studies were AFP studies. 20,24,[30][31][32][33][34][35][36] These studies varied significantly in study design, patient characteristics, and sample size.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Screening tests for hepatocellular carcinoma in patients with chronic hepatitis C: A systematic review

et al. 2002

View full text Add to dashboard Cite

This systematic review addresses the following questions: (1) What is the efficacy of using screening tests for hepatocellular carcinoma (HCC) in improving outcomes in chronic hepatitis C, and (2) what are the sensitivity and specificity of screening tests for HCC in chronic hepatitis C? The search strategy involved searching Medline and other electronic databases between January 1985 and March 2002. Additional articles were identified by reviewing pertinent articles and journals and by querying experts. Articles were eligible for review if they reported original human data from studies of screening tests that used virological, histological, pathologic, or clinical outcome measures. Data collection involved paired reviewers who assessed the quality of each study and abstracted data. One nonrandomized prospective cohort study suggested that HCC was detected earlier and was more often resectable in patients who had twice yearly screening with serum alpha-fetoprotein (AFP) and hepatic ultrasound than in patients who had usual care. Twenty-four studies, which included patients with chronic hepatitis C or B or both, addressed the sensitivities and specificities of screening tests. They were relatively consistent in showing that the sensitivity of serum AFP for detecting HCC usually was moderately high at 45% to 100%, with a specificity of 70% to 95%, for a threshold of between 10 and 19 ng/mL. The few studies that evaluated screening with ultrasound reported high specificity, but variable sensitivity. In conclusion, screening of patients with chronic hepatitis C with AFP and ultrasound may improve detection of HCC, but studies are needed to determine whether screening improves clinical outcomes. (HEPATOLOGY 2002;36:S84-S92.)

show abstract

Urinary transforming growth factor ?1 levels in hepatitis C virus-related chronic liver disease: Correlation between high levels and severity of disease

Cited by 22 publications

References 45 publications

Transforming growth factor beta1 (TGFbeta1) in physiology and pathology

Transforming growth factor beta1 (TGFbeta1) in physiology and pathology

Progression of fibrosis in hepatitis C with and without schistosomiasis: Correlation with serum markers of fibrosis

Screening tests for hepatocellular carcinoma in patients with chronic hepatitis C: A systematic review

Contact Info

Product

Resources

About